In conclusion, GLP-1RAs and GLP-1/GIP dual receptor agonists constitute a landmark advancement in contemporary endocrine and metabolic disease therapy
Not a complicated or nuanced concern The good news for Novo and Lilly is that most of Pfizer's work with PF'3944 is still only in Phase 2 trials, or earlier
eClin Med 58:1 Henn RE, Noureldein MH, Elzinga SE, Kim B, Savelieff MG, Feldman EL (2022) Glial-neuron crosstalk in health and disease: a focus on metabolism, obesity, and cognitive impairment
Common side effects may include mild stomach upset or headache
Rotating injection sites between the abdomen, thigh, and upper arm can minimize this
Other UTSW researchers who contributed to the study are Assistant Professor of Internal Medicine Laurent Gautron, Ph.D., and Research Technicians Bryan Portillo, B.S., Kyle Grose, B.S., and Jason Ajwani, B.S